Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Argus Health
Fish and Richardson
Mallinckrodt
US Army
Dow
Baxter
Boehringer Ingelheim
Citi

Generated: February 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TIMOLOL MALEATE

« Back to Dashboard

Clinical Trials for Timolol Maleate

Trial ID Title Status Sponsor Phase Summary
NCT00108017 Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
NCT00273442 Assessing Cosopt Switch Patients Completed Pharmaceutical Research Network Phase 4 To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.
NCT00273481 Cosopt Versus Xalacom Completed Pharmaceutical Research Network Phase 4 To compare the intraocular pressure efficacy and safety of the DTFC given twice daily versus the LTFC given once every morning following a run-in period with timolol maleate given twice daily.
NCT00330577 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed Aristotle University Of Thessaloniki Phase 4 The purpose of this study is to compare the short-term mean 24-hour intraocular pressure control, 24-hour blood pressure effect and safety of Latanoprost/Timolol fixed combination given once in the evening with placebo once in the morning versus timolol maleate 0.5% given twice daily in patients with ocular hypertension and primary open-angle glaucoma.
NCT00347035 INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE Terminated Federal University of São Paulo Phase 4 Purpose: To evaluate the influence of the nonsteroidal anti-inflammatory indomethacin on the brimonidine intraocular pressure (IOP) lowering effect. Methods: A randomized double-masked study was carried out. Patients medicated with timolol maleate 0,5% and needed complementary medication were random allocated into two groups: (a) brimonidine tartarate 0,15% and indomethacin 1% or (b) brimonidine tartarate and placebo (balanced saline solution). If patient’s both eyes were eligible, they were allocated to the same group. IOP was measured at two weeks, one month and two months after study beginning. The mean IOP of the eyes was used for analyzes, in the case of two eligible eyes. For statistical analyzes repeated measures analysis was used.
NCT00372827 Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension Completed Alcon Research Phase 4 The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.
NCT00435058 Visual Function Changes After Intraocular Pressure Reduction Completed University of Sao Paulo N/A During the glaucomatous disease process, subpopulations of cells may be dead, damaged or healthy. Visual function changes could be observed due to a recovering of the suffering ganglion cells after the intraocular pressure reduction. This study aims at evaluating the correlation between intraocular pressure reduction and visual function changes in glaucoma patients after using antiglaucoma medications.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Timolol Maleate

Condition Name

Condition Name for Timolol Maleate
Intervention Trials
Ocular Hypertension 32
Glaucoma 18
Open-Angle Glaucoma 15
Hemangioma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Timolol Maleate
Intervention Trials
Glaucoma 38
Ocular Hypertension 36
Glaucoma, Open-Angle 31
Hypertension 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Timolol Maleate

Trials by Country

Trials by Country for Timolol Maleate
Location Trials
United States 84
Spain 6
Canada 4
Germany 4
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Timolol Maleate
Location Trials
California 9
New York 6
New Jersey 5
Georgia 5
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Timolol Maleate

Clinical Trial Phase

Clinical Trial Phase for Timolol Maleate
Clinical Trial Phase Trials
Phase 4 21
Phase 3 14
Phase 2 10
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Timolol Maleate
Clinical Trial Phase Trials
Completed 35
Recruiting 9
Active, not recruiting 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Timolol Maleate

Sponsor Name

Sponsor Name for Timolol Maleate
Sponsor Trials
Alcon Research 8
Aerie Pharmaceuticals 5
Allergan 5
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Timolol Maleate
Sponsor Trials
Industry 40
Other 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chinese Patent Office
Moodys
Citi
Queensland Health
Argus Health
Boehringer Ingelheim
Fuji
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.